Theratechnologies Introduces New Treatment Option
EGRIFTA WR™ simplifies treatment for patients with HIV and lipodystrophy by reducing injection frequency.
Convenience and Compliance
Theratechnologies is excited to announce the availability of EGRIFTA WR™ (tesamorelin) for injection, a groundbreaking formulation aimed at significantly reducing excess abdominal fat in adults who are living with HIV and facing lipodystrophy. With its recent approval by the U.S. Food and Drug Administration (FDA), this new formulation is set to replace the prior version, EGRIFTA SV.
Benefits for Patients
Providing enhancements like weekly reconstitution and a reduced daily injection volume, EGRIFTA WR™ addresses the ongoing needs of individuals grappling with the physical effects of HIV. “Excess visceral abdominal fat is a critical health concern, and our goal with EGRIFTA WR™ is to streamline patient care,” stated Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies.
Key Features of EGRIFTA WR™
Unlike its predecessor, EGRIFTA WR™ only requires weekly reconstitution. This means that individuals no longer have to go through daily preparations. Furthermore, the solution is supplied in a package that provides seven daily injections, making it more manageable for users. Each single-patient-use vial contains 11.6 mg of tesamorelin, which is enough for a daily dosage of 1.28 mg injected subcutaneously.
Storage and Instructions
One of the standout aspects of EGRIFTA WR™ is its storage capability—patients can keep it at room temperature, which simplifies its storage needs. The formulation is also patent-protected in the U.S. until 2033, thus ensuring its market exclusivity for the foreseeable future.
Patient Support and Transition
For those transitioning from EGRIFTA SV, Theratechnologies has established the Thera Patient Support program. This initiative assists patients in switching to EGRIFTA WR™ as coverage becomes available through insurance plans. The program is free and provides participants access to dedicated Thera Nurse Navigators who help educate patients on the new formulation and its proper usage.
A Focus on Care
With this initiative, Theratechnologies emphasizes their dedication to patient care. Dr. Marsolais mentioned, “Our goal is to ensure a seamless transition and to continue safeguarding our patients' health and well-being.”
Safety Information
While EGRIFTA WR™ is effective in reducing abdominal fat, there are important safety considerations. It contains a growth hormone-releasing factor (GHRF) analog, which works by stimulating endogenous growth hormone production in the body. However, this treatment is not without its limitations and contraindications. For instance, the long-term cardiovascular safety of EGRIFTA WR™ has not been established. Patients may also face risks if they have a history of specific conditions or are pregnant.
Adverse Reactions
As with any medical treatment, adverse reactions should be monitored. Commonly reported side effects include injection site reactions, arthralgia, pain in extremities, and peripheral edema. It is encouraged for patients and healthcare providers to report any adverse events to the proper authorities to ensure ongoing safety and efficacy.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is at the forefront of biopharmaceutical innovations. The company is committed to developing therapies that redefine care standards for patients with various conditions. Those interested in learning more about Theratechnologies can visit their official website or follow their updates on professional social media platforms.
Frequently Asked Questions
What is EGRIFTA WR™?
EGRIFTA WR™ is an injection treatment designed to reduce excess abdominal fat in adults living with HIV and lipodystrophy.
How does EGRIFTA WR™ differ from its predecessor?
This new formulation simplifies the administration process, requiring weekly reconstitution rather than daily.
What are the common side effects of EGRIFTA WR™?
Adverse reactions can include injection site reactions, arthralgia, pain in extremities, and peripheral edema.
Is there patient support available for using EGRIFTA WR™?
Yes, Theratechnologies offers the Thera Patient Support program to assist patients in transitioning to the new formulation.
How is EGRIFTA WR™ stored?
The product can be stored at room temperature before and after reconstitution, making it easier to manage.
